Cash/Burn From SEC Filing For Period: 

Q4 '19

KPTI

Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.

Cash

$266M

Burn Rate

$50M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

XPOVIO

Multiple myeloma (DLBCL if approved)

Approved (quarterly XPOVIO revenue)

5/8/2020 (estimated)

Selinexor

Multiple myeloma (Penta-Refractory)

Approved/Conditionally

Q3 2019

Selinexor (Xpovio)

Diffuse Large B -Cell Lymphoma DLBCL

PDUFA

6/23/2020

Selinexor

Multiple myeloma (Relapsed/Refractory)

sNDA

June 2020

Selinexor

Liposarcoma

Phase 2/3

Mid - Late 2020

Selinexor

Diffuse Large B- Cell Lymphoma (combination with rituximnab-gemcitabine-dex-platinum)

Phase 3 (XPORT_DLBCL-030)

2020

Selinexor

Endometrial Cancer

Phase 2/3

2021

Eltanexor

myelodisplastic syndrome (MDS)

Phase 2

Eltanexor

Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Phase 1/2

Selinexor

Multiple myeloma (Relapsed/Refractory and Front line)

Phase 1b/2

Selinexor

CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

Phase 2

2020

KPT-9274

cancer

Phase 1

KPT-9274

Solid Tumors & Lymphoma

Phase 1

Selinexor

Diffuse Large B-cell Lymphoma (Combination with Chemo and non-chemo)

Phase 1

2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon